Journal of Peking University(Health Sciences) >
Rheumatoid arthritis combined with pigmented villonodular synovitis: A case report and literature review
Received date: 2020-07-25
Online published: 2020-12-13
We reported a case of rheumatoid arthritis (RA) combined with pigmented villonodular synovitis (PVNS) from Peking University People’s Hospital. The clinical data were introduced and the related literature was reviewed. The clinical features, treatment and prognosis of the disease were summarized to improve clinicians’ understanding of this rare disease and avoid misdiagnosis and delayed diagnosis. A 45-year-old female, with 15 years of RA history and unregular treatment, was admitted to the hospital with the complaint of aggravating pain and swelling in the right knee for 3 months. The puncture of the right knee was performed and there was a large amount of bloody synovial fluid that could not be explained by her RA history. Moreover, the magnetic resonance imaging (MRI) of the right knee revealed hemosiderin deposition with low-intensity signals on both T1-weighted and T2-weighted images which suggested PVNS to us. Then, the patient underwent knee arthroscopy and biopsy to assist in diagnosis. The arthroscopic appearance and pathology were consistent with PVNS and the hyperplastic synovium was removed during arthroscopy. After the operation, she did active functional exercises and took disease-modifying antirheumatic drugs to control RA. She recovered well and remained asymptomatic after half a year of follow-up. Also, there was no recurrence of the right knee. As we all know, RA is a systemic autoimmune disease characterized by chronic synovitis and joint damage. And PVNS is characterized by synovial proliferation and infiltrative process. Both of them are synovial involvement and the clinical manifestations are quite similar. PVNS has occasionally been reported in association with RA. So it is difficult to make a clear diagnosis of RA combined with PVNS. Literature was searched with RA+PVNS in the WanFang Medical Network Database and China National Knowledge Infrastructure and there were no related Chinese cases. Then we searched literature from PubMed with RA+PVNS. The cases were still rare and eventually 2 related articles were yielded including 2 similar patients. It is necessary to fully understand the disease development, complicated MRI appearance and various pathological morpho-logy. They can contribute to making a correct diagnosis which is effective to guide the proper treatment.
Jia-jing PENG , Tian LIU . Rheumatoid arthritis combined with pigmented villonodular synovitis: A case report and literature review[J]. Journal of Peking University(Health Sciences), 2020 , 52(6) : 1135 -1139 . DOI: 10.19723/j.issn.1671-167X.2020.06.025
| [1] | Croia C, Bursi R, Sutera D, et al. One year in review 2019: pathogenesis of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2019,37(3):347-357. |
| [2] | Ottaviani S, Ayral X, Dougados M, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature[J]. Semin Arthritis Rheum, 2011,40(6):539-546. |
| [3] | Hirose I, Mori Y, Fujimoto A. Case report: rheumatoid arthritis occurring during observation after surgery for localized pigmented villonodular synovitis[J]. Mod Rheumatol, 2003,13(3):281-284. |
| [4] | Zhao X, Ji W, Qian X, et al. Pigmented villonodular synovitis developing in a patient with rheumatoid arthritis[J]. J Clin Rheumatol, 2014,20(5):283-286. |
| [5] | Dougados M. Synovial fluid cell analysis[J]. Baillieres Clin Rheumatol, 1996,10(3):519-534. |
| [6] | Myers BW, Masi AT. Pigmented villonodular synovitis and tenosynovitis: A clinical epidemiologic study of 166 cases and literature review[J]. Medicine (Baltimore), 1980,59(3):223-238. |
| [7] | Mastboom M, Verspoor F, Verschoor A, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors[J]. Acta orthopaedica, 2017,88(6):688-694. |
| [8] | Fiocco U, Sfriso P, Lunardi F, et al. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis[J]. Autoimmun Rev, 2010,9(11):780-784. |
| [9] | Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)[J]. Orthop Traumatol Surg Res, 2017,103(1S):S91-S97. |
| [10] | Staals E, Ferrari S, Donati D, et al. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives[J]. Eur J Cancer, 2016,63:34-40. |
| [11] | Cupp J, Miller M, Montgomery K, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides[J]. Am J Surg Pathol, 2007,31(6):970-976. |
| [12] | Oliviero F, Galozzi P, Ramonda R, et al. Unusual findings in synovial fluid analysis: A review[J]. Ann Clin Lab Sci, 2017,47(3):253-259. |
| [13] | 列锐锋. 膝关节色素沉着绒毛结节性滑膜炎MRI表现[J]. 罕少疾病杂志, 2020,27(2):67-69. |
| [14] | Houdek MT, Scorianz M, Wyles CC, et al. Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis[J]. Knee, 2017,24(4):851-855. |
| [15] | Barile A, Sabatini M, Iannessi F, et al. Pigmented villonodular synovitis (PVNS) of the knee joint: magnetic resonance imaging (MRI) using standard and dynamic paramagnetic contrast media. Report of 52 cases surgically and histologically controlled[J]. Radiol Med, 2004,107(4):356-366. |
| [16] | 巫娟, 徐钢, 傅静. 膝关节色素沉着绒毛结节性滑膜炎的临床病理分析[J]. 四川医学, 2017,38(9):1010-1013. |
| [17] | Bernthal N, Ishmael C, Burke Z. Management of pigmented villonodular synovitis (PVNS): an orthopedic surgeon’s perspective[J]. Curr Oncol Rep, 2020,22(6):63. |
| [18] | Palmerini E, Staals E, Maki R, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors[J]. Eur J Cancer, 2015,51(2):210-217. |
| [19] | Tap W, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial[J]. Lancet, 2019,394(10197):478-487. |
| [20] | Monestime S, Lazaridis D. Pexidartinib (TURALIO?): The first FDA-indicated systemic treatment for tenosynovial giant cell tumor[J]. Drugs R D, 2020,20(3):189-195. |
| [21] | Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2018,19(5):639-648. |
/
| 〈 |
|
〉 |